Trinity Life Sciences announced the acquisition of EVERSANA’s advisory services operation across Asia-Pacific and the Middle East (APACME), strengthening its presence in one of the fastest-growing regions for life sciences innovation. The transaction marks a significant expansion of Trinity’s global footprint and underscores its mission to empower life sciences organizations with data-driven strategy, insights, and analytics solutions.
The acquisition brings EVERSANA’s established advisory team in the APACME region under Trinity’s leadership, combining the firms’ complementary expertise in commercialization strategy and local market knowledge. The move extends Trinity’s reach to key cities including Singapore, Tokyo, Mumbai, Shanghai, Sydney, and Dubai. This follows the company’s expansion into Mexico City in July 2025, signaling a broader strategy to offer integrated global support for pharmaceutical, biotech, and medtech clients.
Trinity CEO Leslie Orne said the addition of EVERSANA’s team enhances the company’s ability to deliver localized expertise to clients seeking to scale innovations across diverse international markets. The combined organization aims to provide seamless, end-to-end commercialization support that advances clinical and commercial success at every stage of the product lifecycle.
Founded nearly 30 years ago, Trinity has become a leading global commercialization partner, trusted by more than 350 clients across the life sciences sector. The company has been consistently recognized for its impact, earning a place on Forbes’ 2025 Best Management Consulting Firms list and being named a Leader in Everest Group’s PEAK Matrix for Life Sciences AI and Analytics.
As part of the transaction, Trinity and EVERSANA have also entered a strategic collaboration to jointly serve shared clients in the APACME region. EVERSANA will continue to operate its broader commercialization services, including compliance, field deployment, and market access, while Trinity focuses on expanding its advisory and analytics-driven offerings.
KEY QUOTES:
“Trinity is thrilled to welcome EVERSANA’s APACME team to our global family. This acquisition not only strengthens our footprint in Asia-Pacific and the Middle East but also brings together two high-performing teams dedicated to delivering real-world impact for our clients and the patients they serve. The team’s local leadership, strong client relationships, and proven excellence in consulting are the perfect complements to Trinity’s evidence-based approach and technology-enabled capabilities. Together, we are uniquely positioned to help life sciences companies achieve commercial and clinical success across every stage of the product lifecycle.”
Leslie Orne, CEO of Trinity
